Aqua Medical

Focus: Aqua Medical is a newly founded (2024) medical device company specializing in vapor-based endoscopic ablation therapy for metabolic and rare diseases. The company is publicly listed but remains in early-stage commercialization with no disclosed revenue.

Metabolic Diseases Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$70M

Open Jobs

About Aqua Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Aqua Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

14 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RF Vapor Ablation

Type 2 Diabetes Mellitus

N/A

Clinical Trials (4)

NCT07355270A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)

N/A

Help build intelligence for Aqua Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a 2024-founded public company with differentiated vapor-ablation technology platform spanning multiple indications
Portfolio spans high-impact areas: Type 2 Diabetes (RF Vapor Ablation with 4 trials), lumbar disc herniation, and chronic pain conditions with unmet needs
Rare disease and metabolic focus aligns with growing regulatory incentives and venture investment momentum in these therapeutic areas

Watch Out For

Zero active job openings and no hiring data suggest either minimal team scaling or organizational early stage — unclear growth trajectory
Pre-revenue status with undisclosed funding means limited financial transparency and unknown runway; typical burn-rate risks for early-stage medtech
Pipeline programs lack formal FDA phase designations (all listed as 'N/A') despite 14 active trials, suggesting regulatory clarity gaps

Generated by Claude from Aqua Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT06655740Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes

N/A

NCT06724822RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus

N/A

Kinesiotaping

Neck Pain

N/A

Clinical Trials (1)

NCT04733248kINESIOTAPING ON PATIENT'S FUNCTIONAL STATUS IN NON-SPECIFIC NECK PAIN

N/A

Cervical Proprioceptive Training

Chronic Neck Pain